Business
Telo Genomics Completes International Standards Organization ("ISO") 15189 Final Accreditation
Authorizes Telo to Offer its Laboratory Developed Tests ("LDT") from its Central Lab Toronto, On...
About this update from Telo Genomics Corp.
[{"type":"text","content":"Telo Genomics Completes International Standards Organization (\"ISO\") 15189 Final AccreditationAuthorizes Telo to Offer its Laboratory Developed Tests (\"LDT\") from its Central LabToronto, Ontario--(Newsfile Corp. - October 26, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"Telo\") is pleased to announce that it has passed all requirements and received its Certificate of Accreditation of ISO 15189. Importantly, the rigorous ISO 15189 is the international standard specific for medical laboratories and a key ccomplishment in the commercialization of Telo Genomic's platform of novel cancer assays, which are based-on the 3D analysis of telomeres in measuring genomic instablility.Accreditation Canada Diagnostics (ACD) assessment provides recognition of competence and underscores the facility's experience, superior technical competence and reliability. In addition, ACD is a signatory (ISO 15189) to the Mutual Recognition Arrangement (MRA) of the International Laboratory Accreditation Cooperation (ILAC) and its regional Asia Pacific Accreditation Cooperation (APAC). Certificates granted under this MRA are recognized world-wide including by ILAC's 104 signatories in 105 countries.The certification also validates Point-of-Care Testing (POCT), which authorizes Telo to internationally offer its developed tests from its central laboratory in Toronto, located at the MaRS Discovery District, the world's largest innovation hub dedicated to medical and related sciences.Telo Genomics initial commercial launch will focus on testing for Smoldering Multiple Myeloma (\"SMM\") the precursor for Multiple Myeloma (\"MM\") a deadly blood based bone marrow cancer. There are over 300,000 patients with SMM in the US, with the potential of testing the likelihood of SMM advancing to MM two or more times per year.\"Receiving our ISO 15189 certificate of accreditation concurrent with the commercial launch of our TeloView-SMM test in the US provides an additional layer of confidence in our platform for laboratories and physicians in the myeloma care community,\" stated Kris Weinberg, Telo's CEO. \"The ISO 15189 accreditation confirms the utility of TeloView as a comprehensive platform capable of informing on multiple indications and use cases. We look forward to monetizing our efforts and to fully exploiting oppor...